Biofrontera (BFRI) said Thursday it received US patent approval for the revised formulation of Ameluz, extending protection through to December 2043.
Ameluz is a topical gel used in photodynamic therapy to treat actinic keratoses and certain basal cell carcinomas.
Biofrontera is also studying the medicine for the treatment of moderate to severe acne vulgaris. The company said it had enrolled the final patient in the phase 2b clinical trial of the drug, for a total of 120 subjects.
The company anticipates last-patient-out in Q3, it said.
Shares of Biofrontera were up 1.6% in recent trading.
Price: 0.71, Change: +0.01, Percent Change: +1.57
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.